|
|
| SB202190 |
559388 |
59.8µM |
| SB203580 |
559389 |
85.4µM |
| SKF-86002 |
567305 |
26.1µM |
| MEK1/2 Inhibitor |
444939 |
>100µM |
|
MDS Pharma Services Advantage
- Cell-based assay for more physiologically relevant output
- Minimum compound consumption for 384 well plate format
- Automated, robust and cost-effective
- Accelerated throughput screening (900 compounds per week)
- Objective, consistent and fast
Service Features
- Compound testing in pre-validated human cell line, HeLa
- Direct visualization and automated quantitation of phospho-p38/MAPK
- Minimum compound requirements due to 384 well plate formats and non-contact acoustic energy based compound addition
- A reference compound included as a control on each plate
- 4 week turnaround time
Contact Us
for additional HCA based assay information.
|